BioAge Labs, Inc. has announced an option agreement with JiKang Therapeutics to potentially in-license a novel APJ agonist nanobody, enhancing its pipeline for treating obesity and related metabolic ...
PM ET Event will feature Phase 1 clinical data for BGE-102 and the therapeutic rationale for development in atherosclerotic cardiovascular disease (ASCVD) and retinal disease Four leading academic and ...
CRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose levels Phase 2 proof-of-concept trial in cardiovascular risk planned to ...
BioAge Labs, Inc. announced progress in their development pipeline, highlighting the advancement of their oral NLRP3 inhibitor BGE-102, with initial clinical data expected in the second half of 2025.
The combination of an experimental BioAge Labs drug with the approved Eli Lilly obesity medication Zepbound has hit a major setback: a safety signal observed in some clinical trial participants that ...
Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for obesity New platform partnerships ...
RICHMOND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (BIOA) ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Most of 2025 has been disappointing for BioAge Labs (NASDAQ: BIOA) shareholders, but things are looking up. During the week that ended Oct. 25, shares of the obesity drug developer soared by 46.6%.
The latest price target for Bioage Labs (NASDAQ:BIOA) was reported by Morgan Stanley on December 8, 2025. The analyst firm set a price target for $12.00 expecting BIOA to fall to within 12 months (a ...
BioAge Labs' leading candidate is far too early in the process to make reliable predictions. The biotech will encounter plenty of challengers in its chosen therapeutic area. BioAge Labs (NASDAQ: BIOA) ...
RICHMOND, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results